NCT02166047View on ClinicalTrials.gov

Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants

PHASE2CompletedINTERVENTIONAL

Enrollment

162

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

May 11, 2016

Study Completion Date

October 20, 2016

Conditions

Chronic Hepatitis B

Interventions

DRUG

Vesatolimod

Vesatolimod tablet administered orally

DRUG

Placebo

Placebo to match vesatolimod tablet administered orally

Trial Locations (23)

1142

Auckland

11355

Flushing

20122

Milan

43126

Parma

48202

Detroit

56124

Pisa

71013

San Giovanni Rotondo

90095

Los Angeles

92154

San Diego

94118

San Francisco

95128

San Jose

96734

Honolulu

02111

Boston

02215

Boston

V5Z 1M9

Vancouver

R3E 3P4

Winnipeg

M5G2C4

Toronto

M5T 2S8

Toronto

3015 CE

Rotterdam

110-744

Seoul

120-752

Seoul

135-710

Seoul

138-736

Seoul

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY

NCT02166047 - Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants | Biotech Hunter | Biotech Hunter